Hologic, Inc. (NASDAQ:HOLX) Shares Sold by J. W. Coons Advisors LLC

J. W. Coons Advisors LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 1.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,500 shares of the medical equipment provider’s stock after selling 200 shares during the quarter. J. W. Coons Advisors LLC’s holdings in Hologic were worth $937,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Empowered Funds LLC purchased a new stake in Hologic during the first quarter worth $234,000. Mitsubishi UFJ Trust & Banking Corp grew its stake in Hologic by 0.4% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock valued at $22,490,000 after acquiring an additional 1,136 shares during the last quarter. Acadian Asset Management LLC grew its stake in Hologic by 11,074.7% in the 1st quarter. Acadian Asset Management LLC now owns 179,019 shares of the medical equipment provider’s stock valued at $13,947,000 after acquiring an additional 177,417 shares during the last quarter. Trustmark National Bank Trust Department purchased a new position in shares of Hologic during the 1st quarter worth approximately $204,000. Finally, Seven Eight Capital LP increased its position in Hologic by 35.3% during the first quarter. Seven Eight Capital LP now owns 4,169 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 1,088 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Leerink Partners cut their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Trading Up 1.4 %

Shares of NASDAQ:HOLX opened at $78.60 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a 50 day moving average price of $80.71 and a 200 day moving average price of $78.26.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company posted $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.